An outstanding faculty of speakers from the United States and Europe has committed in this meeting. Based on previous experience, we anticipate attendance by more than 900 scientists, practicing oncologists, basic and clinical, translational investigators and health care workers from all parts of Latin America, USA and Europe.

The conference agenda will focus on new translational advances in the treatment of cancer as well as provide updates of conventional therapies for a number of the most common tumor types. The meeting objectives are designed to introduce the audience to the latest information on targeted therapies, immunotherapies and emerging treatments in early development. The major emphasis will be on clinical aspects of cancer treatment in the 21st century with discussion of significant scientific advances underlying the novel approaches still in preclinical development.

This meeting is the primary opportunity for oncologists and cancer related health workers to participate in a conference focusing on novel targeted therapies and other treatment advances which are changing the face of cancer care.

CO- CHAIRS:
Carlos L. Arteaga, Nashville, USA
Román Perez Soler, New York, USA

SCIENTIFIC COMMITTEE:
Alex Adjei, M.D., Ph.D., Roswell Park Cancer Institute, Buffalo, NY, USA
Kenneth C. Anderson, M.D., Dana-Farber Cancer Institute Boston, USA
Carlos L. Arteaga, M.D., Vanderbilt University School of Medicine, Nashville, USA
Hernán Cortes Funes, M.D., Hospital Universitario "12 de Octubre", Madrid, Spain
Roman Perez Soler, M.D., Albert Einstein College of Medicine, Bronx, NY, USA
Josep Tabernero, M.D., Vall d’Hebron University Hospital, Barcelona, Spain

TOPICS:
New Anticancer Therapies
Breast and Gynaecological Cancer
Gu and Gi Cancer
Lung Cancer
Melanoma
Hematological Malignancies

Location